Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 469

1.

Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.

Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV.

Eur Urol. 2014 Jan;65(1):30-6. doi: 10.1016/j.eururo.2013.06.042.

PMID:
23849416
2.

Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.

Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J.

Eur Urol. 2015 Aug;68(2):317-24. doi: 10.1016/j.eururo.2014.07.028.

PMID:
25108579
3.

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.

Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS.

Eur J Cancer. 2014 Jan;50(1):78-84. doi: 10.1016/j.ejca.2013.08.020.

PMID:
24074764
4.

Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS, Attard G.

Eur Urol. 2014 Sep;66(3):459-65. doi: 10.1016/j.eururo.2013.11.044.

PMID:
24411987
5.

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.

Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES.

Prostate. 2014 Sep;74(13):1278-85. doi: 10.1002/pros.22844.

6.

Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.

Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN.

Eur Urol. 2015 Jan;67(1):23-9. doi: 10.1016/j.eururo.2014.06.045.

PMID:
25018038
7.

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.

Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015.

PMID:
24837187
8.

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.

Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, Coenen JL, van den Eertwegh AJ, de Jong IJ, Kerver ED, van Tinteren H, Bergman AM.

Cancer. 2014 Apr 1;120(7):968-75. doi: 10.1002/cncr.28518.

9.

Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.

Thomsen FB, Røder MA, Rathenborg P, Brasso K, Borre M, Iversen P.

Scand J Urol. 2014 Jun;48(3):268-75. doi: 10.3109/21681805.2013.860189.

PMID:
24255983
10.

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

JAMA Oncol. 2015 Aug;1(5):582-91. doi: 10.1001/jamaoncol.2015.1341.

11.

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.

Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN.

Ann Oncol. 2013 Jul;24(7):1802-7. doi: 10.1093/annonc/mdt138.

PMID:
23585511
12.

Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.

Zhang T, Dhawan MS, Healy P, George DJ, Harrison MR, Oldan J, Chin B, Armstrong AJ.

Clin Genitourin Cancer. 2015 Aug;13(4):392-9. doi: 10.1016/j.clgc.2015.01.004.

PMID:
25708161
13.

Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer.

Schmid SC, Geith A, Böker A, Tauber R, Seitz AK, Kuczyk M, von Klot C, Gschwend JE, Merseburger AS, Retz M.

Adv Ther. 2014 Feb;31(2):234-41. doi: 10.1007/s12325-014-0092-1.

PMID:
24442834
14.

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS, Massard C.

Ann Oncol. 2013 Jul;24(7):1807-12. doi: 10.1093/annonc/mdt136.

PMID:
23576708
15.

Is there an antiandrogen withdrawal syndrome with enzalutamide?

Rodriguez-Vida A, Bianchini D, Van Hemelrijck M, Hughes S, Malik Z, Powles T, Bahl A, Rudman S, Payne H, de Bono J, Chowdhury S.

BJU Int. 2015 Mar;115(3):373-80. doi: 10.1111/bju.12826.

16.

[Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis].

Brodszky V, Péntek M, Baji P, Rencz F, Géczi L, Szûcs M, Berczi C, Gulácsi L.

Magy Onkol. 2014 Sep;58(3):189-97. Review. Hungarian.

17.

A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.

Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, Kollmannsberger C, Heng DY, Joshua AM, Chi KN.

Prostate. 2014 Nov;74(15):1544-50. doi: 10.1002/pros.22872.

PMID:
25175831
18.

Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.

Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES.

Prostate. 2014 Nov;74(15):1560-8. doi: 10.1002/pros.22874.

19.

Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.

Higano CS, Beer TM, Taplin ME, Efstathiou E, Hirmand M, Forer D, Scher HI.

Eur Urol. 2015 Nov;68(5):795-801. doi: 10.1016/j.eururo.2015.01.026.

20.

Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.

Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY.

Prostate Cancer Prostatic Dis. 2015 Jun;18(2):122-7. doi: 10.1038/pcan.2014.53.

Items per page

Supplemental Content

Support Center